End-to-end manufacturing from Grangemouth

The expansion of the site will enhance its ability to deliver the full life cycle of ADC development and manufacturing.

This integrated offering combines the development of the monoclonal antibody, linker/payload, conjugation, and sterile fill and finish into a single integrated program across four global Piramal sites, including Grangemouth.

The approach simplifies development and manufacturing, speeding the process by which new compounds can get to the patients who need them. Programs such as ADCelerate, coupled with the highly skilled workforce in Grangemouth, exemplify how Piramal brings the best science to its customers and their patients.

Support from Scottish Enterprise 

The commissioning of the expanded facility represents the culmination of a £45 million investment to support the rapidly growing demand for ADC manufacturing.

Scottish Enterprise supported the expansion with a £2.4 million grant. Adrian Gillespie, Chief Executive of Scottish Enterprise, commented that “Piramal’s welcome £45 million investment into Scotland’s life sciences sector would create and safeguard high-quality jobs."

Wellbeing Economy Secretary Neil Gray added that the “investment in pharmaceutical innovation helps build on Scotland’s strengths in health and life sciences, creating new jobs and opportunities as part of a fair and growing wellbeing economy. It also augments Grangemouth’s heritage as a critical manufacturing hub for Scotland”.

About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia.

PPS offers a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms.